AdvanDx, Inc. to Unveil QuickFISH™ (20 Min. Pathogen ID) at ECCMID 2012
Published: Mar 15, 2012
QuickFISH is a brand new, rapid, molecular diagnostic platform developed by AdvanDx based on proprietary PNA probe technology. The new platform enables very fast (20 minutes) identification of bacteria directly from such complex samples as positive blood cultures. The speed and ease-of-use will for the first time enable clinical microbiologist to obtain pathogen results, such as S. aureus, E. faecium, P. aeruginosa and Candida species, in time to report with the Gram stain critical values call for positive blood cultures. This, in turn, will help clinicians base therapy selection on more specific information at a critical antibiotic decision point for patients with bloodstream infections.
- 20 Min. Turn-around Time – Fast enough to be reported with Gram stain results.
- 5 Min. Hands-on Time – Simplifies and streamlines laboratory workflow.
- Built-in, Universal Controls – Ensures confidence in every test result.
- Limited Instrumentation Required – Easy and inexpensive to implement and start testing.
Click here to watch QuickFISH Video (YouTube)
To learn more, visit booth # 535 while attending ECCMID 2012 in London or sign up for more news on www.advandx.com.
QuickFISH tests are currently pending United States FDA 510(k) clearance and CE marking.
AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for identification of pathogens that cause critical infections in hospitalized patients. Our mission is to improve antibiotic decision-making and patient outcomes while limiting unnecessary antibiotic use and reducing costs.
AdvanDx employs a unique, Whole Cell Analysis (WCA) approach to pathogen identification using our proprietary Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA FISH) technology platform. This technology enables fast and highly accurate single cell analysis for bacterial species identification in samples from patients with critical infections.
AdvanDx is the market leader in molecular testing of positive blood cultures enabling clinical microbiology labs to report pathogen identification results 48 to 72 hours earlier than with conventional testing methods. When used by physicians and pharmacists to ensure early, appropriate antibiotic therapy for patients with bloodstream infections (a.k.a. septicemia), AdvanDx’s PNA FISH® tests have been shown in clinical studies to reduce mortality rates, shorten length of stay, and lower hospital costs.
For more information visit www.AdvanDx.com
Joen T. Johansen
Director of Marketing